TicagrelorThird Party Manufacturing in India

Ticagrelor works by reversibly binding to the platelet P2Y12 adenosine diphosphate receptor, preventing signal transduction and subsequent platelet activation. Unlike thienopyridines such as clopidogrel, it does not require enzymatic hepatic activation, allowing a faster onset of therapeutic effect and a fully reversible antiplatelet action. It is highly effective and well-tolerated, reducing cardiovascular death and myocardial infarction rates without a proportional increase in severe bleeding events.

Therapeutic Uses

• Acute Coronary Syndrome: Prevention of thrombotic cardiovascular events in patients with unstable angina or myocardial infarction.
• Stroke Prevention: Secondary prevention of ischemic events in high-risk atherosclerotic patients.

Why Manufacturers Choose Ticagrelor

Ticagrelor third party manufacturing in India is highly lucrative due to the massive global and domestic demand for premium cardiovascular therapies. Our partner facilities are WHO-GMP certified and equipped with automated high-speed compression tooling to handle the strict physical parameters of this crystalline entity. Celesta manages efficient volume scale-ups, enabling franchise buyers to capture market share rapidly with high-purity formulations.